Pathophysiology of Hypertension in the Absence of Nitric Oxide/Cyclic GMP Signaling
- First Online:
- Cite this article as:
- Thoonen, R., Sips, P.Y., Bloch, K.D. et al. Curr Hypertens Rep (2013) 15: 47. doi:10.1007/s11906-012-0320-5
- 442 Downloads
The nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signaling system is a well-characterized modulator of cardiovascular function, in general, and blood pressure, in particular. The availability of mice mutant for key enzymes in the NO-cGMP signaling system facilitated the identification of interactions with other blood pressure modifying pathways (e.g. the renin-angiotensin-aldosterone system) and of gender-specific effects of impaired NO-cGMP signaling. In addition, recent genome-wide association studies identified blood pressure-modifying genetic variants in genes that modulate NO and cGMP levels. Together, these findings have advanced our understanding of how NO-cGMP signaling regulates blood pressure. In this review, we will summarize the results obtained in mice with disrupted NO-cGMP signaling and highlight the relevance of this pathway as a potential therapeutic target for the treatment of hypertension.